{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:36Z","timestamp":1791449436575,"version":"4.3.3"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01888-7","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:08:17Z","timestamp":1787278097000},"page":"4857-4872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Anshu","family":"Jonnalagadda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys L.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav N.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar D.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummuguslum","family":"Yildiz-Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Gehlhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9363-945X","authenticated-orcid":false,"given":"Matthew D.","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"1888_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/B978-0-323-54825-0.00013-2","volume-title":"Alopecia","author":"J Fettig","year":"2019","unstructured":"Fettig J, Callaghan D, Goldberg LJ. Discoid lupus erythematosus. In: Miteva M, editor. Alopecia. Elsevier; 2019. p. 151\u20139. https:\/\/doi.org\/10.1016\/B978-0-323-54825-0.00013-2."},{"issue":"1","key":"1888_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000697","volume":"9","author":"C Drenkard","year":"2022","unstructured":"Drenkard C, Theis KA, Daugherty TT, et\u00a0al. Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis. Lupus Sci Med. 2022;9(1):e000697. https:\/\/doi.org\/10.1136\/lupus-2022-000697.","journal-title":"Lupus Sci Med"},{"issue":"2","key":"1888_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5152\/eurasianjmed.2022.21062","volume":"54","author":"MA Melikoglu","year":"2022","unstructured":"Melikoglu MA, Melikoglu M, Demirci E, Barin EZ. Discoid lupus erythematosus-associated cutaneous squamous cell carcinoma in systemic lupus erythematosus. Eurasian J Med. 2022;54(2):204\u20135. https:\/\/doi.org\/10.5152\/eurasianjmed.2022.21062.","journal-title":"Eurasian J Med"},{"key":"1888_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/CCID.S184824","volume":"12","author":"J Company-Quiroga","year":"2019","unstructured":"Company-Quiroga J, Alique-Garc\u00eda S, Romero-Mat\u00e9 A. Current insights into the management of discoid lupus erythematosus. Clin Cosmet Investig Dermatol. 2019;12:721\u201332. https:\/\/doi.org\/10.2147\/CCID.S184824.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1888_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.40018","volume":"69","author":"N Yokogawa","year":"2017","unstructured":"Yokogawa N, Eto H, Tanikawa A, Ikeda T, Yamamoto K, Takahashi T, et\u00a0al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol. 2017;69:791\u20139. https:\/\/doi.org\/10.1002\/art.40018.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1888_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamadermatol.2017.1160","volume":"153","author":"R Fruchter","year":"2017","unstructured":"Fruchter R, Kurtzman DJB, Patel M, Merola J, Franks AG Jr, Vleugels RA, et\u00a0al. Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus. JAMA Dermatol. 2017;153(9):937\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2017.1160.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1888_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaad.2021.09.017","volume":"87","author":"E Keyes","year":"2022","unstructured":"Keyes E, Jobanputra A, Feng R, et\u00a0al. Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: a cohort study. J Am Acad Dermatol. 2022;87(2):447\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2021.09.017.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1888_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/ajd.13571","volume":"62","author":"A Tirado-S\u00e1nchez","year":"2021","unstructured":"Tirado-S\u00e1nchez A, Aguilar-Mena C, Rodriguez-Mendoza A, Hern\u00e1ndez-Salgado Y, Bonifaz A. Clinical-therapeutic study on the efficacy and safety of thalidomide in the management of discoid lupus erythematosus: a single-centre, retrospective study. Australas J Dermatol. 2021;62(3):375\u20139. https:\/\/doi.org\/10.1111\/ajd.13571.","journal-title":"Australas J Dermatol"},{"issue":"7","key":"1888_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/00128071-200304070-00002","volume":"4","author":"P Fabbri","year":"2003","unstructured":"Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003;4(7):449\u201365. https:\/\/doi.org\/10.2165\/00128071-200304070-00002.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1888_CR10","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1111\/jdv.17839","volume":"36","author":"A Calugareanu","year":"2022","unstructured":"Calugareanu A, Grolleau C, Le Buanec H, et\u00a0al. Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus. J Eur Acad Dermatol Venereol. 2022;36(4):e308\u201310. https:\/\/doi.org\/10.1111\/jdv.17839.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1888_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jaut.2013.01.007","volume":"41","author":"C Yu","year":"2013","unstructured":"Yu C, Chang C, Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun. 2013;41:34\u201345. https:\/\/doi.org\/10.1016\/j.jaut.2013.01.007.","journal-title":"J Autoimmun"},{"issue":"9","key":"1888_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","volume":"15","author":"J Wenzel","year":"2019","unstructured":"Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519\u201332. https:\/\/doi.org\/10.1038\/s41584-019-0272-0.","journal-title":"Nat Rev Rheumatol"},{"key":"1888_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jvc2.590","volume":"4","author":"E Parriel","year":"2025","unstructured":"Parriel E, Bulai-Livideanu C, Severino-Freire M, et\u00a0al. Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and DLE (discoid lupus erythematosus). JEADV Clin Pract. 2025;4:207\u201315. https:\/\/doi.org\/10.1002\/jvc2.590.","journal-title":"JEADV Clin Pract"},{"issue":"8","key":"1888_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/0961203316682097","volume":"26","author":"P Vashisht","year":"2017","unstructured":"Vashisht P, Borghoff K, O\u2019Dell JR, Hearth-Holmes M. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017;26(8):857\u201364. https:\/\/doi.org\/10.1177\/0961203316682097.","journal-title":"Lupus"},{"issue":"13","key":"1888_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2217\/imt-2021-0096","volume":"13","author":"M Gonciarz","year":"2021","unstructured":"Gonciarz M, Pawlak-Bu\u015b K, Leszczy\u0144ski P, Owczarek W. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy. 2021;13(13):1135\u201350. https:\/\/doi.org\/10.2217\/imt-2021-0096.","journal-title":"Immunotherapy"},{"key":"1888_CR16","doi-asserted-by":"publisher","first-page":"1217147","DOI":"10.3389\/fmed.2023.1217147","volume":"10","author":"D Nikolopoulos","year":"2023","unstructured":"Nikolopoulos D, Parodis I. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition. Front Med (Lausanne). 2023;10:1217147. https:\/\/doi.org\/10.3389\/fmed.2023.1217147.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1888_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12016-013-8403-x","volume":"47","author":"A Kuhn","year":"2014","unstructured":"Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol. 2014;47(2):148\u201362. https:\/\/doi.org\/10.1007\/s12016-013-8403-x.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"1888_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000086440","volume":"211","author":"HA Miot","year":"2005","unstructured":"Miot HA, Bartoli Miot LD, Haddad GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology (Basel). 2005;211(2):118\u201322. https:\/\/doi.org\/10.1159\/000086440.","journal-title":"Dermatology (Basel)"},{"issue":"4","key":"1888_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jaad.2014.12.025","volume":"72","author":"F Chasset","year":"2015","unstructured":"Chasset F, Franc\u00e8s C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015;72(4):634\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2014.12.025.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1888_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/exd.12957","volume":"25","author":"D Saadeh","year":"2016","unstructured":"Saadeh D, Kurban M, Abbas O. Update on the role of plasmacytoid dendritic cells in inflammatory\/autoimmune skin diseases. Exp Dermatol. 2016;25(6):415\u201321. https:\/\/doi.org\/10.1111\/exd.12957.","journal-title":"Exp Dermatol"},{"key":"1888_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01957","volume":"9","author":"K Sakata","year":"2018","unstructured":"Sakata K, Nakayamada S, Miyazaki Y, et\u00a0al. Up-regulation of TLR7-mediated IFN-\u03b1 production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Front Immunol. 2018;9:1957. https:\/\/doi.org\/10.3389\/fimmu.2018.01957.","journal-title":"Front Immunol"},{"issue":"5","key":"1888_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/0961203308090020","volume":"17","author":"L R\u00f6nnblom","year":"2008","unstructured":"R\u00f6nnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus. 2008;17(5):394\u20139. https:\/\/doi.org\/10.1177\/0961203308090020.","journal-title":"Lupus"},{"key":"1888_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00344","volume":"11","author":"T Fetter","year":"2020","unstructured":"Fetter T, Smith P, Guel T, Braegelmann C, Bieber T, Wenzel J. Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. 2020;11:344. https:\/\/doi.org\/10.3389\/fimmu.2020.00344.","journal-title":"Front Immunol"},{"issue":"11","key":"1888_CR24","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jid.2022.03.033","volume":"142","author":"I Lerman","year":"2022","unstructured":"Lerman I, Bawany F, Whitt W, et\u00a0al. Prominent B-cell signature differentiates discoid from subacute cutaneous lupus erythematosus. J Invest Dermatol. 2022;142(11):2885-2895.e2. https:\/\/doi.org\/10.1016\/j.jid.2022.03.033.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1888_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1358\/dot.2010.46.12.1544336","volume":"46","author":"G Espinosa","year":"2010","unstructured":"Espinosa G, Cervera R. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Drugs Today (Barc). 2010;46(12):891\u20139. https:\/\/doi.org\/10.1358\/dot.2010.46.12.1544336.","journal-title":"Drugs Today (Barc)"},{"issue":"Suppl 4","key":"1888_CR26","doi-asserted-by":"publisher","first-page":"ljad113.069","DOI":"10.1093\/bjd\/ljad113.069","volume":"188","author":"L Carter","year":"2023","unstructured":"Carter L, Wigston Z, Laws P, Vital E. An emerging role of interferon-targeted therapy for the treatment of cutaneous systemic lupus erythematosus: a prospective real-world evaluation of anifrolumab for refractory cutaneous lupus. Br J Dermatol. 2023;188(Suppl 4):ljad113.069.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1888_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080898","volume":"8","author":"A Alunno","year":"2019","unstructured":"Alunno A, Padjen I, Fanouriakis A, Boumpas DT. Pathogenic and therapeutic relevance of JAK\/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells. 2019;8(8):898. https:\/\/doi.org\/10.3390\/cells8080898.","journal-title":"Cells"},{"issue":"4","key":"1888_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa2118024","volume":"387","author":"VP Werth","year":"2022","unstructured":"Werth VP, Furie RA, Romero-Diaz J, et\u00a0al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387(4):321\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2118024.","journal-title":"N Engl J Med"},{"issue":"5","key":"1888_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002954.pub3","volume":"5","author":"S Jessop","year":"2017","unstructured":"Jessop S, Whitelaw DA, Grainge MJ, Jayasekera P. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2017;5(5):CD002954. https:\/\/doi.org\/10.1002\/14651858.CD002954.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1888_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-3083.2007.02427.x","volume":"22","author":"U Wollina","year":"2008","unstructured":"Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol. 2008;22(1):1\u20136. https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02427.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1888_CR31","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/rheumatology\/kei093","volume":"44","author":"A Tlacuilo-Parra","year":"2005","unstructured":"Tlacuilo-Parra A, Guevara-Guti\u00e9rrez E, Guti\u00e9rrez-Murillo F, et\u00a0al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford). 2005;44(12):1564\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kei093.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1888_CR32","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jaad.2008.11.882","volume":"60","author":"I Hemmati","year":"2009","unstructured":"Hemmati I, Otberg N, Martinka M, Alzolibani A, Restrepo I, Shapiro J. Discoid lupus erythematosus presenting with cysts, comedones, and cicatricial alopecia on the scalp. J Am Acad Dermatol. 2009;60(6):1070\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2008.11.882.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1888_CR33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0190-9622(99)70278-1","volume":"41","author":"KR Edwards","year":"1999","unstructured":"Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol. 1999;41(6):1049\u201350. https:\/\/doi.org\/10.1016\/S0190-9622(99)70278-1.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1888_CR34","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/jid.2011.167","volume":"131","author":"S Wahie","year":"2011","unstructured":"Wahie S, Daly AK, Cordell HJ, et\u00a0al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011;131(10):1981\u20136. https:\/\/doi.org\/10.1038\/jid.2011.167.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1888_CR35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453\u201360. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.3459.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1888_CR36","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/art.41683","volume":"73","author":"JT Rosenbaum","year":"2020","unstructured":"Rosenbaum JT, Costenbader KH, Desmarais J, et\u00a0al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthritis Rheumatol. 2020;73(6):908\u201311. https:\/\/doi.org\/10.1002\/art.41683.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1888_CR37","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/archdermatol.2011.191","volume":"147","author":"AY Chang","year":"2011","unstructured":"Chang AY, Piette EW, Foering KP, et\u00a0al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147(11):1261\u20137. https:\/\/doi.org\/10.1001\/archdermatol.2011.191.","journal-title":"Arch Dermatol"},{"issue":"4","key":"1888_CR38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/bjd.16782","volume":"179","author":"IH Yusuf","year":"2018","unstructured":"Yusuf IH, Lotery AJ, Ardern-Jones MR. Joint recommendations for retinal screening in long-term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018. Br J Dermatol. 2018;179(4):995\u20136. https:\/\/doi.org\/10.1111\/bjd.16782.","journal-title":"Br J Dermatol"},{"key":"1888_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.941003","volume":"9","author":"A Verdelli","year":"2022","unstructured":"Verdelli A, Corr\u00e0 A, Mariotti EB, et\u00a0al. An update on the management of refractory cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:941003. https:\/\/doi.org\/10.3389\/fmed.2022.941003.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1888_CR40","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1111\/jdv.18620","volume":"37","author":"G Marzolf","year":"2023","unstructured":"Marzolf G, Lipsker D. Dapsone in non-bullous skin lesions of lupus erythematosus: a literature review. J Eur Acad Dermatol Venereol. 2023;37(2):e189\u201390. https:\/\/doi.org\/10.1111\/jdv.18620.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Pt 2","key":"1888_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S0190-9622(88)70259-5","volume":"19","author":"R Ashinoff","year":"1988","unstructured":"Ashinoff R, Werth VP, Franks AG Jr. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol. 1988;19(5 Pt 2):961\u20135. https:\/\/doi.org\/10.1016\/S0190-9622(88)70259-5.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1888_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semarthrit.2019.07.010","volume":"50","author":"JL Fairley","year":"2020","unstructured":"Fairley JL, Oon S, Saracino AM, Nikpour M. Management of cutaneous manifestations of lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2020;50(1):95\u2013127. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.07.010.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"1888_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archdermatol.2009.30","volume":"145","author":"A Shah","year":"2009","unstructured":"Shah A, Albrecht J, Bonilla-Martinez Z, et\u00a0al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009;145(3):303\u20136. https:\/\/doi.org\/10.1001\/archdermatol.2009.30.","journal-title":"Arch Dermatol"},{"key":"1888_CR44","doi-asserted-by":"publisher","first-page":"2021-9-8","DOI":"10.7573\/dic.2021-9-8","volume":"11","author":"G Malara","year":"2022","unstructured":"Malara G, Verduci C, Altomonte M, et\u00a0al. Thalidomide and discoid lupus erythematosus: case series and review of literature. Drugs Context. 2022;11:2021-9\u20138. https:\/\/doi.org\/10.7573\/dic.2021-9-8.","journal-title":"Drugs Context"},{"issue":"2","key":"1888_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","volume":"147","author":"R Klein","year":"2011","unstructured":"Klein R, Moghadam-Kia S, LoMonico J, et\u00a0al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2010.435.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1888_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/0961203316670731","volume":"26","author":"JK Presto","year":"2017","unstructured":"Presto JK, Hejazi EZ, Werth VP. Biological therapies in the treatment of cutaneous lupus erythematosus. Lupus. 2017;26(2):115\u20138. https:\/\/doi.org\/10.1177\/0961203316670731.","journal-title":"Lupus"},{"issue":"2","key":"1888_CR47","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaad.2025.04.007","volume":"93","author":"DG Rayner","year":"2025","unstructured":"Rayner DG, Gou D, Silang I, et\u00a0al. Comparative effects of biologics and small molecule inhibitors on cutaneous disease activity in lupus erythematosus: a systematic review and network meta-analysis. J Am Acad Dermatol. 2025;93(2):524\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.04.007.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1888_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/mrcr\/rxae018","volume":"8","author":"N Azuma","year":"2024","unstructured":"Azuma N, Natsuaki M, Hashimoto N, et\u00a0al. Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus. Mod Rheumatol Case Rep. 2024;8(2):267\u201371. https:\/\/doi.org\/10.1093\/mrcr\/rxae018.","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"1888_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001007","volume":"10","author":"A Bao","year":"2023","unstructured":"Bao A, Petri MA, Fava A, Kang J. Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE. Lupus Sci Med. 2023;10(2):e001007. https:\/\/doi.org\/10.1136\/lupus-2023-001007.","journal-title":"Lupus Sci Med"},{"issue":"7","key":"1888_CR50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1177\/09612033251337130","volume":"34","author":"S Manzi","year":"2025","unstructured":"Manzi S, S\u00e1nchez-Guerrero J, Yokogawa N, et\u00a0al. The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: a large pooled post\u00a0hoc analysis. Lupus. 2025;34(7):666\u201378. https:\/\/doi.org\/10.1177\/09612033251337130.","journal-title":"Lupus"},{"issue":"8","key":"1888_CR51","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/acr.25058","volume":"75","author":"R Kneeland","year":"2023","unstructured":"Kneeland R, Montes D, Endo J, Shields B, Bartels CM, Garg S. Improvement in cutaneous lupus erythematosus after twenty weeks of belimumab use: a systematic review and meta-analysis. Arthritis Care Res. 2023;75(8):1838\u201348. https:\/\/doi.org\/10.1002\/acr.25058.","journal-title":"Arthritis Care Res"},{"issue":"595","key":"1888_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8442","volume":"13","author":"JL Karnell","year":"2021","unstructured":"Karnell JL, Wu Y, Mittereder N, VIB7734 Trial Investigators, et\u00a0al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. Sci Transl Med. 2021;13(595):eabf8442. https:\/\/doi.org\/10.1126\/scitranslmed.abf8442.","journal-title":"Sci Transl Med"},{"issue":"11","key":"1888_CR53","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie RA, Bruce IN, D\u00f6rner T, et\u00a0al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5397\u2013407. https:\/\/doi.org\/10.1093\/rheumatology\/keab381.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1888_CR54","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1620\/tjem.2022.J074","volume":"258","author":"X Ma","year":"2022","unstructured":"Ma X, Fu X, Cui B, Lin H. Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: a case report and review of the literature. Tohoku J Exp Med. 2022;258(3):219\u201323. https:\/\/doi.org\/10.1620\/tjem.2022.J074.","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"1888_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103723","volume":"24","author":"LA Bokor","year":"2025","unstructured":"Bokor LA, Martyin K, Krebs M, et\u00a0al. Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules: a systematic review and meta-analysis. Autoimmun Rev. 2025;24(3):103723. https:\/\/doi.org\/10.1016\/j.autrev.2025.103723.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1888_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2025-001705","volume":"12","author":"T Witte","year":"2025","unstructured":"Witte T, Fernandez-Ruiz R, Abramova N, et\u00a0al. Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7\/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomized, placebo-controlled phase Ib study. Lupus Sci Med. 2025;12(2):e001705. https:\/\/doi.org\/10.1136\/lupus-2025-001705.","journal-title":"Lupus Sci Med"},{"issue":"3","key":"1888_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clim.2012.09.009","volume":"148","author":"A Markopoulou","year":"2013","unstructured":"Markopoulou A, Kyttaris VC. Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol. 2013;148(3):359\u201368. https:\/\/doi.org\/10.1016\/j.clim.2012.09.009.","journal-title":"Clin Immunol"},{"issue":"4","key":"1888_CR58","doi-asserted-by":"publisher","first-page":"425","DOI":"10.36849\/JDD.7098","volume":"22","author":"S Alsukait","year":"2023","unstructured":"Alsukait S, Learned C, Rosmarin D. Open-label phase 2 pilot study of oral tofacitinib in adult subjects with discoid lupus erythematosus. J Drugs Dermatol. 2023;22(4):425\u20137. https:\/\/doi.org\/10.36849\/JDD.7098.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"1888_CR59","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/ced.15044","volume":"47","author":"A Kreuter","year":"2022","unstructured":"Kreuter A, Licciardi-Fernandez MJ, Burmann SN, Paschos A, Michalowitz AL. Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol. 2022;47(4):787\u20138. https:\/\/doi.org\/10.1111\/ced.15044.","journal-title":"Clin Exp Dermatol"},{"key":"1888_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jdcr.2022.08.038","volume":"28","author":"JJ Park","year":"2022","unstructured":"Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Rep. 2022;28:133\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.038.","journal-title":"JAAD Case Rep"},{"issue":"2","key":"1888_CR61","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1111\/ajd.13514","volume":"62","author":"BP Mumford","year":"2021","unstructured":"Mumford BP, Assarian Z, Oon S, Chong AH. Refractory discoid lupus erythematosus responds to rituximab. Australas J Dermatol. 2021;62(2):e341\u20133. https:\/\/doi.org\/10.1111\/ajd.13514.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"1888_CR62","doi-asserted-by":"publisher","DOI":"10.5070\/D3231033677","volume":"23","author":"A Romero-Mat\u00e9","year":"2017","unstructured":"Romero-Mat\u00e9 A, Garc\u00eda-Donoso C, Hern\u00e1ndez-N\u00fa\u00f1ez A, Mart\u00ednez-Mor\u00e1n C, Moreno-Torres A, Borbujo-Mart\u00ednez J. Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab. Dermatol Online J. 2017;23(1):13030\/qt206538zm.","journal-title":"Dermatol Online J"},{"issue":"3","key":"1888_CR63","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jaad.2024.09.074","volume":"92","author":"VP Werth","year":"2025","unstructured":"Werth VP, Merrill JT, Furie R, et\u00a0al. Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial. J Am Acad Dermatol. 2025;92(3):435\u201343. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.074.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"1888_CR64","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2022-eular.5086a","volume":"81","author":"R Li","year":"2022","unstructured":"Li R, Zhu X, Liu S, et\u00a0al. Orelabrutinib, an irreversible inhibitor of Bruton\u2019s tyrosine kinase (BTK), for the treatment of systemic lupus erythematosus: results of a randomized, double-blind, placebo-controlled, phase Ib\/IIa dose-finding study. Ann Rheum Dis. 2022;81(Suppl 1):210.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"1888_CR65","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3899\/jrheum.2025-0390","volume":"52","author":"B Flamion","year":"2025","unstructured":"Flamion B, Berkani O, Dubois C, Askanase A. Effect of cenerimod on quality of life in systemic lupus erythematosus patients: results from the phase 2 CARE study. J Rheumatol. 2025;52(Suppl 1):183. https:\/\/doi.org\/10.3899\/jrheum.2025-0390.","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"1888_CR66","doi-asserted-by":"publisher","first-page":"KCR.17","DOI":"10.1136\/lupus-2023-KCR.17","volume":"10","author":"B Rovin","year":"2023","unstructured":"Rovin B, Saxena A, Leff R, et\u00a0al. Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: results from the open-label phase 1b\/2 MISSION study. Lupus Sci Med. 2023;10(Suppl 1):KCR.17. https:\/\/doi.org\/10.1136\/lupus-2023-KCR.17.","journal-title":"Lupus Sci Med"},{"key":"1888_CR67","unstructured":"Cabaletta Bio, Inc. Cabaletta Bio presents positive clinical safety and efficacy data on CABA-201 at ACR Convergence 2024. 18 November 2024."},{"key":"1888_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-025-00545-4","volume":"9","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Ma J, Niu J. Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a pharmacovigilance study based on FAERS. BMC Rheumatol. 2025;9:90. https:\/\/doi.org\/10.1186\/s41927-025-00545-4.","journal-title":"BMC Rheumatol"},{"key":"1888_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03389-4","volume":"26","author":"Z Su","year":"2024","unstructured":"Su Z, Zhang C, Gao C, Li C, Li R, Zheng Z. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study. Arthritis Res Ther. 2024;26:163. https:\/\/doi.org\/10.1186\/s13075-024-03389-4.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1888_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041420","volume":"10","author":"C Alves","year":"2020","unstructured":"Alves C, Penedones A, Mendes D, Batel-Marques F. Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses. BMJ Open. 2020;10(12):e041420. https:\/\/doi.org\/10.1136\/bmjopen-2020-041420.","journal-title":"BMJ Open"},{"key":"1888_CR71","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/jvc2.132","volume":"2","author":"I Pereira Amaral","year":"2023","unstructured":"Pereira Amaral I, Antunes J, Soares I, Pupo Correia M, Filipe P. Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: what should a dermatologist know? JEADV Clin Pract. 2023;2:382\u20135. https:\/\/doi.org\/10.1002\/jvc2.132.","journal-title":"JEADV Clin Pract"},{"issue":"4","key":"1888_CR72","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jaad.2008.11.904","volume":"60","author":"A Erceg","year":"2009","unstructured":"Erceg A, Bovenschen HJ, van de Kerkhof PCM, de Jong EMJG, Seyger MMB. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol. 2009;60(4):626\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2008.11.904.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1888_CR73","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3109\/14764172.2013.787802","volume":"15","author":"MP Ekb\u00e4ck","year":"2013","unstructured":"Ekb\u00e4ck MP, Troilius A. Laser therapy for refractory discoid lupus erythematosus when everything else has failed. J Cosmet Laser Ther. 2013;15(5):260\u20135. https:\/\/doi.org\/10.3109\/14764172.2013.787802.","journal-title":"J Cosmet Laser Ther"},{"issue":"2","key":"1888_CR74","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaad.2020.03.123","volume":"83","author":"A Creadore","year":"2020","unstructured":"Creadore A, Watchmaker J, Maymone MBC, Pappas L, Vashi NA, Lam C. Cosmetic treatment in patients with autoimmune connective tissue diseases: best practices for patients with lupus erythematosus. J Am Acad Dermatol. 2020;83(2):343\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.123.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1888_CR75","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-4632.2004.02305.x","volume":"43","author":"B Ramesh","year":"2004","unstructured":"Ramesh B. Discoid lupus erythematosus recurs after plastic surgery. Int J Dermatol. 2004;43(11):859\u201360. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02305.x.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1888_CR76","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3892\/etm.2018.6986","volume":"17","author":"MM Constantin","year":"2019","unstructured":"Constantin MM, Nita IE, Olteanu R, et\u00a0al. Significance and impact of dietary factors on systemic lupus erythematosus pathogenesis. Exp Ther Med. 2019;17(2):1085\u201390. https:\/\/doi.org\/10.3892\/etm.2018.6986.","journal-title":"Exp Ther Med"},{"issue":"6","key":"1888_CR77","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/bjd.17636","volume":"180","author":"ME Ogunsanya","year":"2019","unstructured":"Ogunsanya ME, Cho SK, Hudson A, Chong BF. Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus. Br J Dermatol. 2019;180(6):1430\u20137. https:\/\/doi.org\/10.1111\/bjd.17636.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1888_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081244","volume":"8","author":"CC Berthier","year":"2019","unstructured":"Berthier CC, Tsoi LC, Reed TJ, Stannard JN, Myers EM, Namas R, et\u00a0al. Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes. J Clin Med. 2019;8(8):1244. https:\/\/doi.org\/10.3390\/jcm8081244.","journal-title":"J Clin Med"},{"issue":"4","key":"1888_CR79","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/bjd.17926","volume":"181","author":"M Tarazi","year":"2019","unstructured":"Tarazi M, Gaffney RG, Feng R, Werth VP. Evaluating cutaneous lupus disease activity end points and their effects on quality of life as an outcome measure for clinical trials. Br J Dermatol. 2019;181(4):841\u20132. https:\/\/doi.org\/10.1111\/bjd.17926.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1888_CR80","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2133.2010.09799.x","volume":"163","author":"A Kuhn","year":"2010","unstructured":"Kuhn A, Meuth AM, Bein D, Amler S, Beissert S, B\u00f6hm M, et\u00a0al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163(1):83\u201392. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09799.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1888_CR81","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.2353\/ajpath.2010.100454","volume":"177","author":"MJ Harries","year":"2010","unstructured":"Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J Pathol. 2010;177(5):2152\u201362. https:\/\/doi.org\/10.2353\/ajpath.2010.100454.","journal-title":"Am J Pathol"},{"key":"1888_CR82","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17787.1","volume":"8","author":"KL Chen","year":"2019","unstructured":"Chen KL, Krain RL, Werth VP. Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. F1000Res. 2019;8:F1000 Faculty Rev-332. https:\/\/doi.org\/10.12688\/f1000research.17787.1.","journal-title":"F1000Res"},{"key":"1888_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-el.125","volume":"11","author":"C Foch","year":"2024","unstructured":"Foch C, Souza SD, Sun Y, Chen X, Roy S, Weinelt D, et\u00a0al. Treatment patterns, healthcare resource utilization and related costs of patients with discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) in the United States: a cohort study in the Merative\u2122 MarketScan\u00ae database. Lupus Sci Med. 2024;11:e00125. https:\/\/doi.org\/10.1136\/lupus-2024-el.125.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"1888_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000444","volume":"8","author":"D Yan","year":"2021","unstructured":"Yan D, Zamalin D, Chakka S, Krain R, Concha J, Feng R, et\u00a0al. Cutaneous lupus concerns from the patient perspective: a qualitative study. Lupus Sci Med. 2021;8(1):e000444. https:\/\/doi.org\/10.1136\/lupus-2020-000444.","journal-title":"Lupus Sci Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01888-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:21Z","timestamp":1791446421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01888-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1888"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01888-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Matthew D. Vesely has received consulting fees from SunPharma, Priovant, and Veradermics. Jeffrey R. Gehlhausen has received consulting fees from Priovant and research grants from Bristol Myers Squibb and AstraZeneca. Anshu Jonnalagadda, Rhys L. Richmond, Gaurav N. Pathak, Amar D. Desai, and Ummuguslum Yildiz-Altay have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}